Transdermal Diagnostics

Executive Summary

Transdermal Diagnostics is a UK-based MedTech company developing a non-invasive, needle-free continuous glucose monitoring (CGM) system that leverages hair follicles for glucose extraction. Unlike conventional CGM devices requiring finger-prick calibration, their wearable skin patch and reusable electronics aim to provide a painless, calibration-free experience for diabetes management. The technology addresses key barriers to CGM adoption, including discomfort, complexity, and cost, while also reducing medical waste by reusing electronics. With the global CGM market projected to exceed $20 billion by 2028, Transdermal Diagnostics' solution could capture significant share among insulin-dependent diabetics and health-conscious users seeking proactive monitoring. The company has completed early feasibility studies and is advancing toward pivotal clinical trials for regulatory submission in the UK and Europe. If successful, their platform could disrupt the established CGM oligopoly dominated by Abbott and Dexcom, offering a more accessible and sustainable alternative. However, the technology faces challenges in accuracy validation, manufacturing scalability, and regulatory clearance.

Upcoming Catalysts (preview)

• Q4 2026Pivotal clinical trial results for accuracy validation55% success
• Q1 2027Submission for CE marking under IVDR60% success
• Q2 2027Strategic partnership with a diabetes device or pharma company50% success